SCYNEXIS (SCYX) to Release Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is anticipated to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.1480 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 3:00 PM ET.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.09. SCYNEXIS had a negative net margin of 599.05% and a negative return on equity of 43.04%. The firm had revenue of $1.36 million during the quarter, compared to analysts’ expectations of $0.15 million.

SCYNEXIS Trading Down 3.2%

Shares of NASDAQ SCYX opened at $0.64 on Tuesday. SCYNEXIS has a 1-year low of $0.63 and a 1-year high of $1.49. The company has a 50-day moving average of $0.87 and a two-hundred day moving average of $0.84. The company has a market cap of $26.78 million, a PE ratio of -1.60 and a beta of 1.68.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SCYX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SCYNEXIS in a report on Tuesday, October 14th. Guggenheim decreased their price target on SCYNEXIS from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, October 28th. Finally, Wall Street Zen upgraded SCYNEXIS to a “hold” rating in a research report on Saturday, October 25th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Hedge Funds Weigh In On SCYNEXIS

A hedge fund recently bought a new stake in SCYNEXIS stock. Jane Street Group LLC bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 39,496 shares of the company’s stock, valued at approximately $27,000. Jane Street Group LLC owned 0.10% of SCYNEXIS at the end of the most recent quarter. Institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.